Previous 10 | Next 10 |
2023-06-20 16:24:57 ET Catalent ( NYSE: CTLT ) said Tuesday that Matti Masanovich has been named senior vice president and chief financial officer. The appointment will be effective July 5, 2023. Prior to joining Catalent, Masanovich served as...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023. Prior to joining Catalent, Mr. Masanovi...
2023-06-16 10:45:50 ET Maravai LifeSciences ( NASDAQ: MRVI ) rose 2.2% amid a report of takeover interest from a strategic buyer for the vaccine reagent vendor. An unidentified strategic buyer is said to be competing with private equity firm Thomas H. Lee for Maravai ( M...
2023-06-14 04:11:09 ET Catalent ( NYSE: CTLT ) said NYSE has notified the biotech company about having regained compliance with the stock exchange's continued listing standards. The company filed its Quarterly Report on Form 10-Q for the three and nine month...
Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) announced today that the Company has received written notification (“Notice”) from the New York Stock Exchange (“NYSE”) that it has officially regained compliance with the NYSE contin...
2023-06-12 12:55:06 ET Catalent, Inc. (CTLT) Q3 2023 Earnings Conference Call June 12, 2023 8:15 A.M. ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President and Chief Executive Officer Ricky Hopson - Interim Chief ...
2023-06-12 10:02:21 ET Contract manufacturer Catalent ( NYSE: CTLT ) added ~11% in the morning hours Monday after finally beating Street forecasts with its Q3 report for FY23, following numerous delays. Catalent's ( CTLT ) revenue for the quarter surpassed expectati...
2023-06-12 07:03:10 ET Catalent press release ( NYSE: CTLT ): Q3 Non-GAAP EPS of -$0.09 beats by $0.05 . Revenue of $1.04B (-19% Y/Y) beats by $68.26M . Updated FY'23 financial guidance projects net revenue of $4,225 million to $4,325 million and Adjusted EBITD...
Q3'23 net revenue of $1.04 billion decreased 19% as reported, or 17% in constant currency (1) , compared to Q3'22. Organic, constant-currency net revenue decreased by 19%, compared to Q3'22. Q3'23 net loss of $(227) million, including a goodwill impairment of $210 million. ...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the third quarter of fiscal year 2023 ended March 31, 2023, before the market open on Monday, June 12, 2023. The C...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...